The founders were thrilled when Perlmutter, widely lauded for turning Merck & Co. into an immuno-oncology powerhouse, agreed to come on as CEO after retiring at the end of 2020. “I’m sure he’s had dozens and dozens of incoming opportunities, and he can be the scientific chairman of any company,” says Brad Loncar, CEO of life sciences–focused Loncar Investments.
by Lisa M. Jarvis | May 05, 2021
/pharmaceuticals/oncology/Radiopharma-firm-ITM-raises-109/99/i16 20210430 Concentrates 99 16 /magazine/99/09916.html Radiopharma firm ITM raises $109 million pharmaceuticals, oncology, radiopharmaceuticals con bus Ryan Cross pharmaceuticals oncology business investment Radiopharma firm ITM raises $109 million Chemical & Engineering News Radiopharma firm ITM raises $109 million Radiopharma firm ITM raises $109 million
by Ryan Cross | April 30, 2021
His research focused on sickle cell anemia, cardiovascular disease, stroke, cancer, Alzheimer’s disease, and radiation oncology. Equal to his professional passion for research and teaching was his big heart in helping people. He loved his family and took us everywhere he went. He also always took extra time to help anyone, friend or stranger, regardless of their situation, be it increasing faith in God, financial issues, or their golf swing.
by Linda Wang | April 24, 2021
Last year, Heller, who eventually left academia to lead oncology teams at multiple drug companies, joined and became vice president of R&D at a start-up called Jasper Therapeutics, which is trying to make conditioning safer and more effective. It is one of a handful of companies—including Actinium Pharmaceuticals, Gilead Sciences, and Magenta Therapeutics—developing antibody-based therapies designed to selectively remove hematopoietic stem cells with fewer side effects than traditional conditioning.
by Ryan Cross | April 18, 2021
A graphic showing the numbers of gene, cell-based immuno-oncology, cell, and tissue engineering therapies in Phases 1, 2, and 3. Photo of research scientists at work in a biologics-oriented laboratory. A table showing the seven cell and gene therapies to win US Food and Drug Administration approval since 2017.
by Rick Mullin | April 18, 2021
/pharmaceuticals/oncology/Sanofi-acquires-Tidal-Therapeutics/99/i14 20210417 Concentrates 99 14 /magazine/99/09914.html Sanofi acquires Tidal Therapeutics oncology, pharmaceuticals, mrna con bus Ryan Cross pharmaceuticals oncology business mergers-&-acquisitions Sanofi acquires Tidal Therapeutics Chemical & Engineering News Sanofi acquires Tidal Therapeutics Sanofi acquires Tidal Therapeutics
by Ryan Cross | April 17, 2021
/pharmaceuticals/oncology/Theseus-launches-pan-variant-kinase/99/i14 20210416 Concentrates 99 14 /magazine/99/09914.html Theseus launches for pan-variant kinase inhibitors Oncology, kinase inhibitors, small molecules con bus Michael McCoy pharmaceuticals oncology Theseus launches for kinase inhibitors Chemical & Engineering News Theseus launches for pan-variant kinase inhibitors Theseus launches for pan-variant kinase inhibitors
by Michael McCoy | April 16, 2021
/pharmaceuticals/oncology/Novartis-pay-13-billion-develop/99/i13 20210409 Concentrates 99 13 /magazine/99/09913.html Novartis to pay up to $1.3 billion to develop synthetic lethality therapies with Artios drug discovery, cancer, startups con bus Megha Satyanarayana pharmaceuticals oncology Novartis, Artios team for synthetic lethality Chemical & Engineering News Novartis to pay up to $1.3 billion to develop synthetic lethality therapies with Artios Novartis to pay up to $1.3 billion to develop synthetic lethality therapies with Artios
by Megha Satyanarayana | April 09, 2021
The start-up has not disclosed its other programs but says it is interested in autoimmune, inflammation, oncology, and neurology indications. /pharmaceuticals/drug-discovery/Ventus-raises-100-million-drug/99/i13 20210409 Concentrates 99 13 /magazine/99/09913.html Ventus raises $100 million to drug innate immune system drug discovery, pharmaceuticals con bus Ryan Cross pharmaceuticals drug-discovery Ventus targets the innate immune system Chemical & Engineering News Ventus raises $100 million to drug innate immune system Ventus raises $100 million to drug innate immune system
by Ryan Cross | April 09, 2021
Attaching polyethylene glycol (PEG) to specific points in the amino acid chain of IL-2 makes the construct bigger, lengthening its half-life, says Willem Overwijk, vice president of oncology research at Nektar Therapeutics. Nektar’s lead IL-2 candidate, bempegaldesleukin, or bempeg, features six strands of PEG attached to lysines on aldesleukin, the active ingredient in Proleukin.
by Megha Satyanarayana | April 04, 2021